Exscientia Initiates Prospective Observational Study in Ovarian Cancer
18 Julho 2023 - 8:00AM
Business Wire
First multi-centre trial, EXCYTE-1, evaluating
the potential of Exscientia’s functional precision medicine
platform in solid tumour indication
Builds off of pioneering AI-guided functional
precision medicine research in haematological cancers
Exscientia plc (Nasdaq: EXAI) today announced the initiation of
EXCYTE-1, a prospective observational study in ovarian cancer to
investigate the relationship between ex vivo drug response (EVDR)
in primary tumour-derived samples using the company’s precision
medicine platform and actual patient clinical response. This first
of its kind observational study in solid tumours will run at
multiple medical research centres in Europe with a focus on ovarian
cancers. It aims to inform and enable future studies in other solid
tumours.
Ovarian cancer represents a high unmet need for predicting
patient response to diverse therapy options. The study will be
conducted in collaboration with the Arbeitsgemeinschaft
Gynäkologische Onkologie (AGO) Study Group, one of the leading
non-profit clinical research networks in gynaeco-oncology
worldwide.
“We are thrilled to work with Exscientia to advance the state of
science and potential treatment of ovarian cancer patients," said
Professor Philipp Harter M.D., Ph.D., Head of Gynaecology and
Gynaeco-Oncology at Evangelische Kliniken Essen-Mitte, Germany, and
Chair of the AGO Study Group. "This study will enable us to explore
new ways to identify the right treatment for individual patients,
especially in cases with no available molecular biomarkers. We look
forward to being a part of this important scientific
evaluation.”
By combining high-content imaging of samples and deep learning
image analysis, the company’s AI-based precision medicine platform
leverages a patient’s biopsies to assess drug activity at a single
cell level ex vivo. The EXCYTE-1 trial follows the prospective
EXALT-1 trial in haematologic malignancies, the first study to
leverage AI-driven ex vivo drug testing to guide treatment
selection and improve outcomes in patients with advanced
haematological cancers. Patients who received drugs prioritised by
the platform experienced significantly better outcomes, with 54% of
patients demonstrating clinical benefit of >1.3-fold enhanced
progression free survival (PFS) compared to prior therapy. The
EXCYTE-1 trial is designed to expand the scope of Exscientia’s
precision medicine platform in solid tumours.
“The outcomes from this study could have broad implications for
how we evaluate drug candidates and support clinical practice in
the future,” said Dr. Nikolaus Krall, EVP of Precision Medicine at
Exscientia. “If established, a robust correlation between our
platform’s results and clinical outcomes will support the greater
use of human tumour samples in the preclinical development of new
drug candidates and translational cancer research. This has the
potential to overcome the limited clinical relevance of mouse and
other animal models that are presently used. In addition, this
study may further pave the way for the use of functional drug
testing to guide treatment selection to achieve better patient
outcomes.”
About EXCYTE-1 Prospective Observational Study
The EXCYTE-1 trial is a multi-centre two-phase study evaluating
the correlation between clinical and ex vivo drug response as
measured using Exscientia’s AI-based precision medicine platform in
ovarian cancer. The study is designed to compare results from the
precision medicine platform to clinical outcomes via tissue
collection and drug response analysis.
The objective of the pilot phase of the study is to collect
patient tissue samples and analyse the drug response of the tissue
in a lab setting before scaling up to a larger expansion phase. Two
patient populations will be included: patients newly diagnosed with
advanced ovarian cancer and those with relapsed ovarian cancer.
Before undergoing therapy, malignant ascites will be collected,
accompanied by solid tissues where available. The EVDR of commonly
used standard of care therapies will then be evaluated in these
patient samples by Exscientia’s AI-based precision medicine
platform. These results will be compared against patients’ clinical
response to treatment, which will be chosen and evaluated by
physicians blinded to the EVDR data. Progression free survival
(PFS) of patients will be monitored as the key clinical endpoint
and assessed to monitor association with EVDR. Secondary endpoints
will include EVDR predicted early relapse and PFS >12
months.
About Exscientia
Exscientia is an AI-driven precision medicine company committed
to discovering, designing and developing the best possible drugs in
the fastest and most effective manner. Exscientia developed the
first-ever functional precision oncology platform to successfully
guide treatment selection and improve patient outcomes in a
prospective interventional clinical study, as well as to progress
AI-designed small molecules into the clinical setting. Our internal
pipeline is focused on leveraging our precision medicine platform
in oncology, while our partnered pipeline broadens our approach to
other therapeutic areas. By pioneering a new approach to medicine
creation, we believe the best ideas of science can rapidly become
the best medicines for patients.
Visit us at https://www.exscientia.ai or follow us on Twitter
@exscientiaAI.
Exscientia Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the collaboration with the AGO
Study Group; and the timing and progress of, and data collected
during and reported from, the EXCYTE-1 clinical trial, as well as
expectations with respect to the outcome or benefit of such trial.
Any statement describing Exscientia’s goals, plans, expectations,
intentions or beliefs is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to a
number of risks, uncertainties and assumptions, including those
related to: the initiation, scope and progress of Exscientia’s and
its partners’ planned and ongoing pre-clinical studies and clinical
trials and ramifications for the cost thereof; clinical,
scientific, regulatory and technical developments; the process of
discovering, developing and commercialising product candidates that
are safe and effective for use as human therapeutics; and the
endeavour of building a business around such product candidates. In
light of these risks and uncertainties, and other risks and
uncertainties that are described in the Risk Factors section and
other sections of Exscientia’s Annual Report on Form 20-F, filed
with the Securities and Exchange Commission (SEC) on March 23, 2022
(File No. 001-40850), and other filings that Exscientia makes with
the SEC from time to time (which are available at
https://www.sec.gov/), the events and circumstances discussed in
such forward-looking statements may not occur, and Exscientia’s
actual results could differ materially and adversely from those
anticipated or implied thereby. Although Exscientia’s
forward-looking statements reflect the good faith judgement of its
management, these statements are based only on facts and factors
currently known by the Company. As a result, you are cautioned not
to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718014000/en/
Investor Relations: Sara Sherman
investors@exscientia.ai
Media: Oliver Stohlmann media@exscientia.ai
Exscientia (NASDAQ:EXAI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Exscientia (NASDAQ:EXAI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024